The chief executive of New Jersey’s fourth-largest biotech company resigned on Monday, done in by backdated executive stock options that have sparked a shareholders suit, a grand jury subpoena and a Securities and Exchange Commission investigation.

Medarex Inc., of Princeton, N.J., joins a growing list of businesses, including McAfee Inc. and Monster Worldwide Inc., where a CEO has stepped down in the wake of stock-option-related litigation and regulatory investigations.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]